TG4010 A therapeutic vaccine against MUC1 expressing tumors

被引：39
|
作者：
Limacher, Jean-Marc [1 ]
Quoix, Elisabeth [2 ]
机构：
[1] Transgene SA, Illkirch Graffenstaden, France
[2] Nouvel Hop Civil, Hop Univ Strasbourg, Strasbourg, France
来源：
ONCOIMMUNOLOGY | 2012年 / 1卷 / 05期
关键词：
non-small cell lung cancer; cancer vaccine; TG4010; biomarker; CELL LUNG-CANCER; IMMUNOTHERAPY; CHEMOTHERAPY; MVA-MUC1-IL2;
D O I：
10.4161/onci.19863
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TG4010 is a therapeutic cancer vaccine based on a viral vector, a modified vaccinia of Ankara (MVA), expressing MUC1 as well as interleukine 2. Today the clinical development is focused on advanced non-small cell lung cancer in combination with first line chemotherapy. Potential biomarkers predictive of activity have been identified.
引用
收藏
页码：791 / 792
页数：2
相关论文
共 50 条
  • [21] POSTTRANSLATIONAL PROCESSING OF MUC1 BY PANCREATIC TUMORS
    HOLLINGSWORTH, MA
    INTERNATIONAL JOURNAL OF PANCREATOLOGY, 1994, 16 (2-3) : 258 - 259
  • [22] VACCINIA VIRUS MUC1 IMMUNIZATION OF MICE - IMMUNE-RESPONSE AND PROTECTION AGAINST THE GROWTH OF MURINE TUMORS BEARING THE MUC1 ANTIGEN
    ACRES, RB
    HAREUVENI, M
    BALLOUL, JM
    KIENY, MP
    JOURNAL OF IMMUNOTHERAPY, 1993, 14 (02) : 136 - 143
  • [23] MUC1 expressing tumor growth was retarded after human mucin 1 (MUC1) plasmid DNA immunization
    Son, Hye-Youn
    Jeong, Hwan-Kyu
    Apostolopoulos, Vasso
    Kim, Chul-Woo
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2022, 36
  • [24] RETRACTION: MUC1 expressing tumor growth was retarded after human mucin 1 (MUC1) plasmid DNA immunization
    Son, H. Y.
    Jeong, H. K.
    Apostolopoulos, V
    Kim, C. W.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2025, 39
  • [25] Immune mechanisms of the response to TG4010, a viral-based vaccine, in patients with advanced non-small cell lung carcinoma
    Bendjama, Kaidre
    Quemeneur, Eric
    Bastien, Berangere
    Brandely-Talbot, Maud
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [26] Tolerance and immunity to tumor-associated antigen MUC1 in MUC1.Tg mice
    Ryan, Sean O.
    Turner, Michael S.
    Revers, Leigh
    Gariepy, Jean
    Finn, Olivera J.
    FASEB JOURNAL, 2008, 22
  • [27] Investigating the role of IDO in MUC1 expressing breast cancers
    Besmer, Dahlia
    Kidiyoor, Amritha
    Nath, Sritama
    Das Roy, Lopamudra
    Curry, Jennifer
    Mukherjee, Pinku
    CANCER RESEARCH, 2012, 72
  • [28] A phase II study evaluating the clinical efficacy of TG4010 (MVA-MUC1-IL2) in association with cisplatin and vinorelbine in patients with non small cell lung cancer
    Mennecier, B
    Ramlau, R
    Rolski, J
    Lena, H
    Pless, M
    Levy, E
    Krzakowski, M
    Hess, D
    Limacher, J
    Velu, T
    LUNG CANCER, 2005, 49 : S373 - S373
  • [29] Tri-component MUC1 glycopeptide vaccine induced both humoral and cellular immune responses in MUC1.Tg mice with MMT tumor
    Lakshminarayanan, Vani
    Thompson, Pamela
    Wolfert, Margreet
    Bradley, Judy
    Pathangey, Latha
    Madsen, Cathy
    Cohen, Peter
    Boons, Geert-Jan
    Gendler, Sandra
    JOURNAL OF IMMUNOLOGY, 2011, 186
  • [30] MUC1 and MUC2 expression in salivary gland tumors.
    Merzianu, M
    Ghali, W
    Wenig, BM
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 120 (03) : 458 - 458
12345